Testing a combination targeted therapy (ViPOR) for aggressive B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination of targeted drugs called ViPOR for people with aggressive B-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this treatment can help when standard therapies haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of aggressive B-cell lymphoma confirmed by biopsy.
- Your lymphoma has returned or not gotten better after at least one prior treatment that included an anthracycline drug and an anti-CD20 antibody (like rituximab).
- You have measurable disease (a tumor that can be seen on scans).
- You have good organ function (kidney, liver, blood counts) as determined by tests.
- You are willing to provide a tumor sample from a previous biopsy or undergo a new biopsy if needed.
- You have not had certain other treatments recently, such as chemotherapy within the past 2 weeks or more than 3 prior lines of chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding tafasitamab, lenalidomide, tazemetostat, and zanubrutinib (along with standard lymphoma treatment) can improve outcomes in people whose large B-cell lymphoma has returned or not responded. It may help control disease more effectively and improve response duration for eligible patients.
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
This trial tests two targeted drugs, zanubrutinib and sonrotoclax, together for people with certain types of B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. It focuses on enrolling patients from racial and ethnic groups that are often underrepresented in research.
This Phase 1/2 trial tests a combination of several medicines (venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid) for lymphoma that has come back or did not respond. It aims to shrink tumors safely and improve responses in people with specific types of B-cell lymphoma.
This trial tests a combination of three drugs (mosunetuzumab, polatuzumab vedotin, and lenalidomide) for people with diffuse large B-cell lymphoma (a type of blood cancer) that has come back or not responded to previous treatment. The goal is to see if this combination is safe and effective.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
Hear when a new Recurrent Diffuse Large B-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.